IMRX today
$3.60-$0.07 (-2.04%)close Nov 13, 2026Trend
DailyDowntrend (confirmed)
4 hourStrong Bearish
1 hourStrong Bearish
15 minStrong Bearish
5 minStrong Bearish
Daily trend turns up above $3.96
Key levels
Resistance$4.23
Resistance$3.95
Support$3.44
Support$2.90
Latest news & SEC filings
DealImmuneering and Astellas Pharma agree to joint clinical work
ProductImmuneering announces Phase 2 trial of atebimetinib in anaplastic thyroid cancer
DealImmuneering to supply atebimetinib for two Astellas pancreatic cancer trials
ProductImmuneering to start Phase 2 trial of atebimetinib with chemotherapy in anaplastic thyroid cancer
All IMRX news →About Immuneering
Immuneering is a clinical-stage oncology business creating a novel category of cancer therapies known as Deep Cyclic Inhibitors. Its most advanced drug, atebimetinib, is an oral MEK inhibitor under study for pancreatic tumors and other solid cancers, given by itself or alongside other treatments. A second clinical program, envometinib, plus earlier discovery efforts round out its pipeline. The company serves cancer patients and their physicians, running trials across the United States and additional countries.
Based on the company's 10-K filed Mar 6, 2026.
Nasdaq · Healthcare
Immuneering Corp (IMRX)
What Is the Price Target for IMRX?
SEPT Low Target
$14.00
SEPT Mid Target
$16.00
SEPT High Target
$18.00
Analyst Consensus
$16.00
Is IMRX a Buy or Sell Right Now?
Thesis
- •Revenue growing -84.8% YoY with UNKNOWN trend — consistent growth.
- •Smart money flows are positive — institutional and insider activity shows net buying.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for IMRX.
Start Free Trial →Is IMRX Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
P/B, Analyst Consensus
Fair Value
$13.68
12
Moat Score
NONE
4/9
Piotroski Score
5.8
Altman Z-Score
What Is Smart Money Doing with IMRX?
Insider Signal
BUYING
5 buys / 0 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →IMRX Growth Story
Revenue YoY
-84.8%
3yr Revenue CAGR
N/A%
EPS Growth YoY
37.75%
FCF Growth YoY
17.4%
Revenue Trend
UNKNOWN
Dark Pool Trades for IMRX
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for IMRX, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 16:46:10 | $3.58 | 1,200 | $$4K | SELL |
| 16:45:32 | $3.58 | 19,957 | $$71K | SELL |
| 16:37:14 | $3.58 | 5,000 | $$18K | MIDPOINT |
| 16:31:45 | $3.58 | 1,500 | $$5K | MIDPOINT |
| 16:15:49 | $3.55 | 1,408 | $$5K | MIDPOINT |
5 dark pool trades shown · $$104K preview volume
Real-time institutional flow, block trades, and net positioning
What Traders Are Saying About IMRX
1 postsSEPT Investing hosts an active community of 3,500+ traders sharing real-time analysis, trade setups, and market discussion for IMRX. Join verified traders discussing price action, dark pool alerts, options flow, and AI-powered market intelligence.
$imrx is on the schedule for wed nov 11.
Join 3,500+ traders discussing IMRX in real-time
Trade ideas, setups, dark pool alerts, and AI-powered analysis
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for Immuneering Corp (IMRX) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (3 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →IMRX — frequently asked questions
What is IMRX stock price today?
Immuneering Corp (IMRX) is at $3.60, down 2.04% (-$0.07) at the Nov 13, 2026 close.
Why is IMRX stock down today?
Nov 12, 2026: Immuneering announced a collaboration with Astellas Pharma to jointly conduct clinical work, including supplying its experimental drug atebimetinib for two Astellas-run pancreatic cancer trials. The company also said it will start a Phase 2 trial of atebimetinib in anaplastic thyroid cancer, both as a monotherapy and in combination with chemotherapy.
What is the IMRX price target?
The average analyst price target for IMRX is $16.00, ranging from $14 to $18, based on 2 analysts. Latest: HC Wainwright & Co. initiates on Aug 6, 2026.
What do analysts rate IMRX?
Analyst ratings for IMRX: 2 Buy, 1 Hold, 0 Sell — consensus Buy.
Did IMRX beat earnings?
IMRX last reported on Oct 29, 2026: EPS -$0.37 vs -$0.29 expected — a miss of 27.6%.
Does IMRX pay a dividend?
IMRX does not currently pay a dividend.
What are IMRX support and resistance levels?
Support: $3.44, $2.90, $2.40. Resistance: $3.95, $4.23, $4.67.
What are insiders doing with IMRX?
Insider activity: BUYING, 5 buys and 0 sells in the last 90 days.
What is the latest news on IMRX?
Nov 12, 2026: Immuneering and Astellas Pharma agree to joint clinical work · Nov 12, 2026: Immuneering announces Phase 2 trial of atebimetinib in anaplastic thyroid cancer · Nov 12, 2026: Immuneering to supply atebimetinib for two Astellas pancreatic cancer trials